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Background
DNA vaccines expressing the HIV-1 envelope (Env) have
been relatively ineffective at generating high-titer, long-
lasting, immunity. Conjugating the molecular adjuvant,
C3d, to HIV-1 Env enhances both humoral and cellular
immunity.
Methods
BALB/c mice were vaccinated with DNA plasmids (weeks
0, 4, and 8) expressing wild-type or modified envelope
proteins. Each Env immunogen was tested alone or conju-
gated to multiple copies of the molecular adjuvant, C3d.
Both humoral and cellular immunity were analyzed.
Results
DNA vaccines expressing a fusion protein of the soluble
human CD4 (sCD4) and the Envgp120 enhanced the
immunogenicity of the expressed fusion protein only
when conjugated to mC3d3. Monoclonal antibodies that
recognize CD4-induced epitopes on Envgp120 efficiently
bound to sCD4-gp120 or sCD4-gp120-mC3d3. In addi-
tion, both molecules bound to cells expressing appropri-
ate coreceptors in the absence of cell surface hCD4. Mice
vaccinated with DNA plasmids expressing either gp120-
mC3d3 or sCD4-gp120-mC3d3 elicited antibodies that
neutralized homologous virus infection. However, the use
of sCD4-gp120-mC3d3-DNA elicited the highest titers of
neutralizing antibodies that persisted after depletion of
anti-hCD4 antibodies. Interestingly, only mice vaccinated
with DNA expressing sCD4-gp120-mC3d3 had antibodies
that elicited cross-protective neutralizing antibodies. In a
separate set of experiments, the unique sequence found in
the crown of the V3 loop of the envelope from the CD4-
independent isolate, HIV-1R2, was used to elicit cross-
clade neutralizing antibodies. The codons encoding for
the V3 loop amino acids, Pro-Met, were introduced into
the sequences encoding the gp120ADA (R5) or gp12089.6
(R5X4). Mice vaccinated with gp120ADA-mC3d3-DNA
with the Pro-Met mutation had antibodies that neutral-
ized HIV-1 infection, but not the gp12089.6-mC3d3-DNA.
Conclusion
Therefore, the use of sequences that expose cryptic
epitopes by CD4 or found in CD4-independent viral iso-
lates expose neutralizing epitopes that can elicit broad,
cross-clade immunity.
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